A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral in vivo

Journal of Gene Medicine

Volumn 8, Issue 10, 2006, Pages 1232-1242

  Li, Binghua ^a   Liu, Xinran ^a   Fan, Junkai ^a   Qi, Rong ^a   Bo, Linan ^a   Gu, Jinfa ^a   Qian, Qijun ^b   Qian, Cheng ^b   Liu, Xinyuan ^a,b  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

Non apoptotic cell death; Oncolytic adenovirus; Survivin promoter

Indexed keywords

ANTINEOPLASTIC AGENT; LUCIFERASE; MESSENGER RNA; SURVIVIN E1A FUSION PROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS VECTOR; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SPECIFICITY; FEMALE; GENE EXPRESSION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MOLECULAR CLONING; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOLYTIC VIRUS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; UPREGULATION; VIRAL GENE THERAPY;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL DEATH; CELLS, CULTURED; CLONING, MOLECULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HELA CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; ONCOLYTIC VIRUSES; PROMOTER REGIONS (GENETICS); TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA;

EID: 33750526892     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.953     Document Type: Article

References (34)

1. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-727.
2. Dobbelstein M. Replicating adenoviruses in cancer therapy. Curr Topics Microbiol Immunol 2004; 273: 291-334.
3. McCormick F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther 2003; 2: S157-160.
4. Ries S, Korn WM. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer 2002; 86: 5-11.
5. Wirth T, Zender L, Schulte B, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 2003; 63: 3181-3188.
6. Ruan DT, Warren RS. Liver-directed therapies in colorectal cancer. Semin Oncol 2005; 32: 85-94.
7. Zou W, Luo C, Zhang Z, et al. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 2004; 23: 457-464.
8. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17: 2941-2953.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
10. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
11. Tamm I, Wang Y, Sausville E, et al. LAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315-5320.
12. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-584.
13. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998; 273: 11177-11182.
14. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A 2001; 98: 635-640.
15. Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 2004; 23: 39-48.
16. Bao R, Connolly DC, Murphy M, et al. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 2000; 94: 522-528.
17. Chen JS, Liu JC, Shen L, et al. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 2004; 11: 740-747.
18. Gu J, Fang B. Telomerase promoter-driven cancer gene therapy. Cancer Biol Ther 2003; 2: S64-70.
19. Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther 2002; 9: 30-37.
20. Suzuki K, Alemany R, Yamamoto M, Curiel DT. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 2002; 8: 3348-3359.
21. Kanerva A, Hemminki A. Modified adenoviruses for cancer gene therapy. Int J Cancer 2004; 110: 475-480.
22. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 2001; 7: 781-787.
23. Kruyt FA, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 2002; 13: 485-495.
24. Jakubczak JL, Ryan P, Gorziglia M, et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 2003; 63: 1490-1499.
25. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000, 106: 763-771.
26. Yang YJ, Zheng XF, Zhu J, Lu X, Luo Y, Sun ZX. [Expression of osm gene driven by hTERT gene promoter inhibits cancer cells proliferation in vitro], Ai Zheng 2003; 22: 575-578.
27. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001, 108: 981-990.
28. Uchida H, Tanaka T, Sasaki K, et al. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 2004; 10: 162-171.
29. Yang L, Cao Z, Li F, et al. Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther 2004; 11: 1215-1223.
30. Kamizono J, Nagano S, Murofushi Y, et al. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication. Cancer Res 2005; 65: 5284-5291.
31. Marcellus RC, Teodoro JG, Wu T, et al. Adenovirus type 5 early region 4 is responsible for E1A-induced p53-independent apoptosis. J Virol 1996; 70: 6207-6215.
32. Abou El Hassan MAI, van der Meulen-Muileman I, Abbas S, Kruyt FAE. Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J. Virol 2004; 78: 12243-12251.
33. Ito H, Aoki H, Kuhnel F, et al. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst 2006; 98: 625-636.
34. Levine B, Yuan J. Autophagy in cell death: an innocent convict? J. Clin. Invest 2005; 115: 2679-2688.